Invention Grant
- Patent Title: Pan-ELR+ CXC chemokine antibodies
-
Application No.: US15695338Application Date: 2017-09-05
-
Publication No.: US10093727B2Publication Date: 2018-10-09
- Inventor: Catherine Brautigam Beidler , Kristine Kay Kikly , Beth Ann Strifler , Derrick Ryan Witcher , Sudhakar Reddy Chintharlapalli
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Duane Christopher Marks; Xiaoguang Gao
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C07K16/24 ; C07K16/32
Abstract:
Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
Public/Granted literature
- US20170362315A1 Pan-ELR+ CXC CHEMOKINE ANTIBODIES Public/Granted day:2017-12-21
Information query
